Quality by Design (QbD) is a method approach to developing a quality control system using predetermined objectives. It uses the foundations of risk management and science to ensure a repeatable process to manufacture high-quality products. In 2002, the FDA launched QbD as part of its innovation initiative. This paper outlines resources for increasing productivity, decreasing cost and implementing a quantifiable, conclusive and cost-effective monitoring strategy.
In the 21st century, it is no longer possible to release products or monitor processes (especially aseptically-filled sterile products) using microbiological methodologies and techniques developed in the 20th century. The use of outdated microbiological analytical methods allows the detection of a third of the microorganisms present in the product/process. Therefore, it is not possible to completely identify areas of contamination in the production process.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Strategies and implementation of more sensitive and/or more reliable microbiological analytical methodologies that allow the identification of potential production process problems and their resolution should be a priority.
Microbiological monitoring
Critical pharmaceutical processes, both non-sterile (aerosol) and sterile (injectables), must be monitored in order to ensure quality of the final product. Environmental monitoring systems are an important part of aseptic processing, and an essential component of controlling the presence, distribution, and survival of microorganisms. Examples of critical non-sterile products include aerosol, nasal spray and powder inhalers.
Improved detection results in the improvement of microbiological quality. However, this increase in microbiological quality and sensitivity must coincide proportionately with production costs. To ensure reasonable cost, realistic goals must be set.
Monitoring cannot identify and quantify all microbial contaminants. Microbiological monitoring of a cleanroom is technically a semi-quantitative exercise, given the limitations in sampling equipment. Lack of precise counting methods and limited sampling volumes mean that environmental monitoring is incapable of providing quantitative information regarding sterility assurance.
Decreasing production costs
It is possible for production costs to decrease with an increase in microbiological quality. For example, in production, when two batches are rejected or multiple OOS are found, the investigations can total $15,000-$50,000 each. Areas of poor quality must first be identified and their cost calculated. If possible, operators should be removed from the aseptic process due to the strong impact humans have on microbiological contamination. Inspectors are indicating that the common CAPA towards non-conclusive results – “operator error means operator training/re-training” – is no longer acceptable more than once a year. Poor microbiological techniques and methods contribute to difficulty in quantifying this impact. Critical areas for monitoring include process waters (deionised, RO and WFI), air and compressed gases, and surfaces including personnel, gloves and equipment.
An increase in aseptic process understanding, as well as the implementation of QbD can also reduce costs for the manufacturer. Regulatory authorities are leaning towards the introduction of restricted access barrier systems (RABS) or the use of isolator systems (eg, cooling zone of a decontamination tunnel (grade A), not microbiologically monitored), which reduce costs by decreasing operator intervention. The introduction of new or alternative microbiological monitoring techniques can also cut long-term costs of traditional methods.
FDA initiatives for innovation
In early 2002, the US FDA recognised the need for the pharma industry to be more innovative and launched:
A critical path initiative
Pharmaceutical Quality for the 21st Century – A Risk Based Approach
Quality by design (QbD)
Process analytical technology (PAT).
Over the past few years, the agency has implemented the concepts of QbD into its pre-market processes. The focus of this concept is that quality should be built into a product with an understanding of the product and process by which it is developed and manufactured. Complete knowledge of the risks involved in manufacturing and how best to mitigate them is also essential. This is a successor to the ‘quality by QC’ (or ‘quality after design’) approach that companies used into the 1990s.
Figure 1: Typical microbial contamination sources in a manufacturing environment
Understanding risk
To ensure a robust process, regulatory bodies encourage the monitoring of the complete manufacturing process. Continuous monitoring is already common practice in non-viable particle monitoring. However, particles can be viable, non-viable, viable but nonculturable (VBNC), and sometimes even all-in-one, and should be monitored in the same capacity. Risk assessments of aseptic filling lines reveal that frequent or continuous sampling is preferable.
Until now, microbiological monitoring had limited capabilities to meet these requirements. For years, passive four-hour sampling was used as the sole method of monitoring. However, the plates are largely influenced by sampling errors, impossible to validate and are non-conclusive (data is acquired via gravitation, and influenced by particle size and air velocity).
In addition, intervention must be taken by operators to change out the plate every so many hours, often leading to an increased amount of investigations due to false positives. The end result is an increased cost of goods, sterilisation, cleaning, stock, and incoming tests.
Regulatory agencies have agreed on the concept of gravitational settling in order to attain a minimum amount of data about the whole manufacturing process. This concept is obsolete due to its related costs, and there has been a shift towards continuous air monitoring.
The first alternative to passive monitoring, deemed active air monitoring, used typical sampling times of 10 minutes at 100LPM to 120 minutes at 25LPM as the standard for active monitoring devices.
Mitigating risk
Air and surface samples should be taken at the locations where significant activity or product exposure occurs during production. When identifying critical sites to be sampled, consideration should be given to the points of contamination risk in a process. Air monitoring samples of critical areas should normally yield no microbiological contaminants. We recommend affording appropriate investigative attention to contamination occurrences in this environment. Any intervention or stoppage during an aseptic process can increase the risk of contamination. The design of equipment used in aseptic processing should limit the number and complexity of aseptic interventions by personnel.
The FDA aseptic filling guide says: “Both personnel and material flow should be optimised to prevent unnecessary activities that could increase the potential for introducing contaminants to exposed product, container closures, or the surrounding environment.” Similar requirements to this quote can be found in other regulations, like ISO, EU GMP and USP. But how can you sample close to critical control points without adding a risk of contamination to the product and therefore to the patient? Sampling points are determined by risk analysis as the locations with the highest risk of contamination, and the use of air sampling devices can contribute significantly to particle creation in critical areas, especially those that do not use HEPA filtration.
Conclusion
QbD is a common approach to modern pharmaceutical manufacturing. Continuous viable air monitoring at low flow rates (25LPM) is essential to understanding the risk of a manufacturing process. Single-use technologies can mitigate and remove the risk of air sampling close to critical control points, and decrease costs of cleaning, sanitisation and sterilisation of reusable equipment.
Using low-impact, conclusive sampling techniques to increase productivity results in reduced OOS/OOT, costs of investigation and regulatory interactions and argumentations. The impact of new and alternative monitoring technologies on labour costs in the laboratory and in manufacturing can be significant.
Biographies
GILBERTO DALMASO is the Senior Consultant and Pharma Customer Advisory Team Manager at Particle Measuring Systems. He has over 25 years’ experience in pharmaceutical microbiology and sterility assurance. His current work is focused on pharmaceutical microbiology and aseptic processes, microbiological contamination control and rapid microbiological methods, QbD, and PAT in microbiology.
FRANK PANOFEN is Sterility Assurance/Microbiology Product Line Manager at Particle Measuring Systems. He has been an invited speaker at international conferences including ECA and PDA, with a strong regulatory background in pharmaceuticals. He is a certified Microbiological Laboratory Manager from ECA.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.